美股新聞 標題聯播 · 近 24 小時 267 則 · 24 個來源 · 最新 9/20 07:24
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · EYPT近 30 天 6 則 · 第 1 / 1 頁
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Street Calls of the Week
- EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO
- Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls
- Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, GitLab, GLOBAL FOUNDRIES, Martin Marietta Materials, Rocket Lab USA, Strategy, Toast, Tower Semiconductor, and More
- EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
- These 2 Stocks Are Setting Off Technical Alarm Bells with $1,000+ Price Tags. Here’s the Company I’d Bet on for the Long Term.
- EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says
- EyePoint’s Duravyu falls short to Eylea in Phase III trial
- Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls
- EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’
- EyePoint (EYPT) LUGANO Data Resets The Story, Is It A Bargain?
- EyePoint (EYPT) Is Down 62.7% After DURAVYU Misses Phase 3 Endpoint In Wet AMD Trial – Has The Bull Case Changed?
- Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today?
- OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
- The Surprising Reason EyePoint Just Crashed 67%, Sacrificing A Breakout
- EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.
- Sector Update: Healthcare Stocks Mixed Monday Afternoon
- EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial
- EyePoint DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint as Secondary Data Show Reduced Treatment Burden
- EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。